CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells.
Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究展示了一种用于胃肠道肿瘤治疗的强效靶向 GUCY2C 的 CAR-T 细胞,并强调了充分的 tonic 信号对 CAR-T 细胞有效治疗实体瘤的重要性。
嵌合抗原受体(CAR)T 细胞在实体瘤治疗中面临多项障碍,包括抗原表达异质性和 T 细胞持久性不足。由于鸟苷酸环化酶 C(GUCY2C)在正常组织中的表达局限于肠道,并在胃肠道肿瘤、尤其是结直肠癌中持续过表达,因此已被认为是合适的靶向治疗肿瘤抗原。本研究考察一种对抗原敏感且具有持久性的 GUCY2C 靶向 CAR-T 细胞。
利用构建的 GUCY2C 表达密度不同的肿瘤细胞系,我们筛选出一种抗原敏感的单链可变片段(scFv),使 CAR-T 细胞能够有效清除 GUCY2C 低表达肿瘤细胞。我们还构建了铰链区、跨膜区和共刺激结构域组成不同的 CAR-T 细胞,并筛选在体外和荷瘤小鼠中具有持久抗肿瘤疗效的 CAR-T 构型。随后通过突变铰链区和跨膜区进一步研究其机制。
由抗原敏感 scFv、CD8 铰链区、CD8 跨膜区和 CD28 共刺激结构域组成的 CAR,可促使 CAR-T 细胞在多种结直肠癌模型中快速杀瘤、保持较强扩增能力并维持长期疗效。其持久抗肿瘤功能归因于适度的 CAR 持续性信号;即使没有抗原刺激,该信号也能赋予 CAR-T 细胞自主激活、增殖、生存和细胞因子释放能力。持续性信号与 CD8 铰链区和跨膜区的长度及半胱氨酸残基有关。
本研究展示了一种用于胃肠道肿瘤治疗的强效 GUCY2C 靶向 CAR-T 细胞,并强调适度持续性信号对 CAR-T 细胞有效治疗实体瘤的重要性。
Chimeric antigen receptor (CAR)-T cells face many obstacles in solid tumor therapy, including heterogeneous antigen expression and inefficient T cell persistence. Guanylyl cyclase C (GUCY2C) has been identified as a suitable tumor antigen for targeted therapy due to its intestinal-restricted expression pattern in normal tissues and steady overexpression in gastrointestinal tumors, especially colorectal cancer. An antigen-sensitive and long-lasting CAR-T cell targeting GUCY2C was investigated in this study.
Using constructed tumor cell lines with various GUCY2C expression densities, we screened out an antigen-sensitive single chain variable fragment (scFv) that enabled CAR-T cells to efficiently eradicate the GUCY2C lowly expressed tumor cells. CAR-T cells with different compositions of the hinge, transmembrane and costimulatory domains were also constructed for selection of the long-lasting CAR-T format with durable antitumor efficacy in vitro and in tumor-bearing mice. The underlying mechanism was further investigated based on mutation of the hinge and transmembrane domains.
We found that the composition of the antigen-sensitive scFv, CD8 hinge, CD8 transmembrane, and CD28 costimulatory domains boosted CAR-T cells to rapidly kill tumors, maintain high expansion capacity, and long-term efficacy in various colorectal cancer models. The durable antitumor function was attributed to the optimal CAR tonic signaling that conferred CAR-T cells with autonomous activation, proliferation, survival and cytokine release in the absence of antigen stimulation. The tonic signaling was associated with the length and the cysteine residues in the CD8 hinge and transmembrane domains.
This study demonstrated a potent GUCY2C-targeted CAR-T cell for gastrointestinal tumor therapy and highlights the importance of adequate tonic signaling for effective CAR-T cell therapy against solid tumors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。